The heat is on as we are now less than two weeks away from the US midterm elections. President Donald Trump has announced a plan to lower prices for some prescription drugs and has said it could end unfair practices that force Americans to pay more for drugs than people in other countries do for the same medications.
Though these would only apply to drugs administered in doctors’ offices, this could impact an array of companies. Despite these latest developments, a number of companies are making a push to take advantage of the new attention that the healthcare space is receiving. Companies like Premier Health Group, Inc. (PHGRF)(PHGI.CN), Intellipharmaceutics International Inc. (IPCI)(IPCI.TO) and Actinium Pharmaceuticals, Inc. (ATNM)
Premier Health Group, Inc. (PHGRF)(PHGI.CN)
Premier Health Group, Inc. (PHGRF)(PHGI.CN) continued to trade above the $0.70 mark on Thursday. The company has opened its publicly traded shares to be more easily traded in the US. Premier Health Group, Inc. (PHGRF)(PHGI.CN) announced this week that its common shares traded on the OTC Markets Group Inc.’s OTCQB Venture Market in the United States, under the symbol “PHGRF”, are Depository Trust Company (“DTC”) eligible, effective October 22, 2018. DTC eligibility allows Premier Health shares to be more easily and economically transferred between brokerage accounts electronically within the United States
Statistics from Premier Health Group, Inc. (PHGRF)(PHGI.CN)’s subsidiary, HealthVue show that roughly 15% of Canadians aged 12 and older don’t have a primary care physician. Nearly two-thirds of seniors are also unable to get a same-or next-day appointment. This contributes to about 7 in 10 Canadians avoiding seeing a doctor when they are sick. “The HealthVue patient app powered by Reliq Health’s technology platform will allow patients to book appointments, see their GP or a specialist via telemedicine, review their own chart, chat with clinic staff and pharmacists, refill prescriptions, and share health data collected in the home with their HealthVue care team,” said Dr. Essam Hamza, MD, CEO of HealthVue.
Intellipharmaceutics International Inc. (IPCI)(IPCI.TO)
Intellipharmaceutics International Inc. (IPCI)(IPCI.TO) is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company’s patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals.
Today Intellipharmaceutics announced that it has received a letter from the Hearings Advisor from the Nasdaq Office of General Counsel notifying the Company that it had regained compliance with Nasdaq’s stockholders’ equity requirement. The letter also informed the Company that the Company will remain subject to a “Panel Monitor” under Nasdaq Listing Rule 5815(d)(4)(A) until October 22, 2019.
The letter noted that while the Company is not out of compliance with Nasdaq’s minimum bid price rule because its common shares have not traded below $1.00 for 30 consecutive trading days, the Company’s shares have closed below $1.00 since October 11, 2018, and indicated that if at any time during the monitor period the Company fails any Nasdaq listing standard, the Nasdaq Staff will issue a Staff Delisting Determination and the Hearings Department will schedule a hearing.
Actinium Pharmaceuticals, Inc. (ATNM)
Actinium Pharmaceuticals, Inc. (ATNM) announced today that the company will host a conference call and webinar this morning at 11:00 AM ET to provide key updates on the advancement of its CD33 program that is based on the Antibody RadiationConjugate (ARC), Ac-225 – Lintuzumab. Actinium is developing its CD33 program for hematologic indications including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM).
According to the release, today’s call will highlight Actinium’s post-Phase 2 development plans following completion of its Actimab-A trial in patients newly diagnosed with AML who are over the age of 60 and unfit for intensive chemotherapy. In addition, management will provide an update on the regulatory pathway for Actimab-MDS following positive interactions with the U.S. Food and Drug Administration (FDA).
Shares of Actinium saw highs of over $0.70USD during premarket hours on Friday.
5 Additional Healthcare Stocks Trending On Friday:
Synergy Pharmaceuticals Inc. (SGYP)
Bristol-Myers Squibb Company (BMY)
Amarin Corporation plc (AMRN)
MYnd Analytics, Inc. (MYND)
Proteostasis Therapeutics, Inc. (PTI)
The healthcare industry will continue to drive the nation’s employment growth through 2026 by adding around 4 million new jobs, accounting for about a third of total job growth, according to data from the Bureau of Labor Statistics(1). Technology like telemedicine and artificial intelligence will complement clinicians and ease their burden rather than replace them and for these reasons, the market potential for healthcare stocks and technology stocks related to healthcare industry players could present long-term potential in the years to come.
(1)Bureau of Labor Statistics: https://www.bls.gov/news.release/pdf/ecopro.pdf
This blog is affiliated with Midam Ventures LLC. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid “500,000” shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2018 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer
Biotech Breakroom 